• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should we use bisphosphonates to treat bone complications in sickle cell disease?

作者信息

Gollamudi Jahnavi, Adesina Oyebimpe

机构信息

Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.

Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA.

出版信息

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):623-626. doi: 10.1182/hematology.2024000671.

DOI:10.1182/hematology.2024000671
PMID:39644017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11665504/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf6/11665504/eb9d571074c4/hem.2024000671_s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf6/11665504/eb9d571074c4/hem.2024000671_s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daf6/11665504/eb9d571074c4/hem.2024000671_s1.jpg

相似文献

1
Should we use bisphosphonates to treat bone complications in sickle cell disease?我们应该使用双膦酸盐来治疗镰状细胞病的骨并发症吗？
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):623-626. doi: 10.1182/hematology.2024000671.
2
Bisphosphonates in multiple myeloma.双膦酸盐在多发性骨髓瘤中的应用
Cochrane Database Syst Rev. 2010 Mar 17(3):CD003188. doi: 10.1002/14651858.CD003188.pub2.
3
Bisphosphonates in multiple myeloma: a network meta-analysis.双膦酸盐类药物治疗多发性骨髓瘤：一项网状Meta分析
Cochrane Database Syst Rev. 2012 May 16(5):CD003188. doi: 10.1002/14651858.CD003188.pub3.
4
Inhaled nitric oxide for treating pain crises in people with sickle cell disease.吸入一氧化氮治疗镰状细胞病患者的疼痛危象。
Cochrane Database Syst Rev. 2022 Jul 8;7(7):CD011808. doi: 10.1002/14651858.CD011808.pub3.
5
Bisphosphonates in multiple myeloma.双膦酸盐在多发性骨髓瘤中的应用
Cochrane Database Syst Rev. 2002(3):CD003188. doi: 10.1002/14651858.CD003188.
6
Bisphosphonates in multiple myeloma.双膦酸盐在多发性骨髓瘤中的应用
Cochrane Database Syst Rev. 2001(4):CD003188. doi: 10.1002/14651858.CD003188.
7
Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease.定期长期输注红细胞用于治疗镰状细胞病的慢性胸部并发症。
Cochrane Database Syst Rev. 2016 May 20(5):CD008360. doi: 10.1002/14651858.CD008360.pub4.
8
Bisphosphonates for steroid-induced osteoporosis.双膦酸盐用于治疗类固醇诱导的骨质疏松症。
Cochrane Database Syst Rev. 2016 Oct 5;10(10):CD001347. doi: 10.1002/14651858.CD001347.pub2.
9
Bisphosphonates for advanced prostate cancer.双膦酸盐用于晚期前列腺癌。
Cochrane Database Syst Rev. 2017 Dec 26;12(12):CD006250. doi: 10.1002/14651858.CD006250.pub2.
10
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲（羟脲）治疗镰状细胞病。
Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202. doi: 10.1002/14651858.CD002202.pub3.

本文引用的文献

1
Exagamglogene Autotemcel for Severe Sickle Cell Disease.依洛尤单抗治疗严重镰状细胞病。
N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24.
2
A bone to pick-cellular and molecular mechanisms of bone pain in sickle cell disease.棘手问题——镰状细胞病骨痛的细胞和分子机制
Front Pain Res (Lausanne). 2024 Jan 4;4:1302014. doi: 10.3389/fpain.2023.1302014. eCollection 2023.
3
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
洛沃细胞基因治疗镰状细胞病：HGB-206 研究初始组的治疗过程演变和结果。
Am J Hematol. 2023 Jan;98(1):11-22. doi: 10.1002/ajh.26741. Epub 2022 Oct 10.
4
Sickle cell bone disease and response to intravenous bisphosphonates in children.镰状细胞性骨病和儿童静脉内双膦酸盐的反应。
Osteoporos Int. 2022 Nov;33(11):2397-2408. doi: 10.1007/s00198-022-06455-2. Epub 2022 Jul 29.
5
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.多发性骨髓瘤相关骨病的治疗：国际骨髓瘤工作组骨工作组的建议。
Lancet Oncol. 2021 Mar;22(3):e119-e130. doi: 10.1016/S1470-2045(20)30559-3. Epub 2021 Feb 2.
6
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.美国血液学会2020年镰状细胞病指南：急性和慢性疼痛的管理
Blood Adv. 2020 Jun 23;4(12):2656-2701. doi: 10.1182/bloodadvances.2020001851.
7
Development of Algorithm for Clinical Management of Sickle Cell Bone Disease: Evidence for a Role of Vertebral Fractures in Patient Follow-up.镰状细胞性骨病临床管理算法的开发：椎体骨折在患者随访中作用的证据
J Clin Med. 2020 May 25;9(5):1601. doi: 10.3390/jcm9051601.
8
Bleeding in patients with sickle cell disease: a population-based study.镰状细胞病患者的出血情况：一项基于人群的研究。
Blood Adv. 2020 Mar 10;4(5):793-802. doi: 10.1182/bloodadvances.2019000940.
9
Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease.尿交联羧基末端肽，一种骨吸收标志物，在镰状细胞病成人血管阻塞危象后下降。
Blood Cells Mol Dis. 2020 Feb;80:102369. doi: 10.1016/j.bcmd.2019.102369. Epub 2019 Oct 24.
10
Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results.身高校正后的低骨密度与镰状细胞病的严重结局相关：SCCRIP 队列研究结果。
Blood Adv. 2019 May 14;3(9):1476-1488. doi: 10.1182/bloodadvances.2018026047.